SlideShare uma empresa Scribd logo
1 de 11
Sorafenib
[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Interaction
Fecal  ( 77% )  and renal (19%)   Excretion 25-48hours Half life Hepatic oxidation and glucuronidation (CYP3A4 mediated) Metabolism 99,5% Protein binding 29-49% Bioavailability
[object Object],[object Object],[object Object],[object Object],[object Object],Contraindication
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],Refrence

Mais conteúdo relacionado

Mais procurados (19)

Drug induced blood disorders
Drug induced blood disordersDrug induced blood disorders
Drug induced blood disorders
 
Hyperlipidemias
HyperlipidemiasHyperlipidemias
Hyperlipidemias
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
 
IVMS-CV Pharmacology-Hyperlipidemia Agents
IVMS-CV Pharmacology-Hyperlipidemia AgentsIVMS-CV Pharmacology-Hyperlipidemia Agents
IVMS-CV Pharmacology-Hyperlipidemia Agents
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Hyperlipidemia
Hyperlipidemia Hyperlipidemia
Hyperlipidemia
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
 
Shelly hyperlipidemia
Shelly hyperlipidemiaShelly hyperlipidemia
Shelly hyperlipidemia
 
lipid lowering and atherosclerosis
lipid lowering and atherosclerosislipid lowering and atherosclerosis
lipid lowering and atherosclerosis
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Polycythemia by Dr. Sookun Rajeev Kumar
Polycythemia by Dr. Sookun Rajeev KumarPolycythemia by Dr. Sookun Rajeev Kumar
Polycythemia by Dr. Sookun Rajeev Kumar
 
Proteinuria, A medical student prespective
Proteinuria, A medical student prespectiveProteinuria, A medical student prespective
Proteinuria, A medical student prespective
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia
 
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMSEssential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
Essential thrombocythemia (2019) by Dr Shami Bhagat SKIMS
 
Pharmacotherapy of Dyslipidemias
Pharmacotherapy of DyslipidemiasPharmacotherapy of Dyslipidemias
Pharmacotherapy of Dyslipidemias
 
Antihyperlipidemia
AntihyperlipidemiaAntihyperlipidemia
Antihyperlipidemia
 
Polycythemia vera
Polycythemia veraPolycythemia vera
Polycythemia vera
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 

Destaque

Drugs.com : Metformies
Drugs.com : MetformiesDrugs.com : Metformies
Drugs.com : Metformiesdrucsamal
 
Prostate Cancer: Keep Takling The Androgenic Nature
Prostate Cancer: Keep Takling The Androgenic NatureProstate Cancer: Keep Takling The Androgenic Nature
Prostate Cancer: Keep Takling The Androgenic NatureMohamed Abdulla
 
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...European School of Oncology
 
World castration resistant prostate cancer therapeutics - market
World castration resistant prostate cancer therapeutics - market   World castration resistant prostate cancer therapeutics - market
World castration resistant prostate cancer therapeutics - market Allied Market Research
 
ECCLU 2011 - K. Fizazi - Prostate cancer drug development
ECCLU 2011 - K. Fizazi - Prostate cancer drug developmentECCLU 2011 - K. Fizazi - Prostate cancer drug development
ECCLU 2011 - K. Fizazi - Prostate cancer drug developmentEuropean School of Oncology
 
ARV7 splice variant in CRPC
ARV7 splice variant in CRPCARV7 splice variant in CRPC
ARV7 splice variant in CRPCMohsin Maqbool
 
Treatment of advanced metastatic prostate cancer
Treatment of advanced metastatic prostate cancerTreatment of advanced metastatic prostate cancer
Treatment of advanced metastatic prostate cancerCatherine Holborn
 
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016Mohamed Abdulla
 
Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy
Enzalutamide in Metastatic Prostate Cancer Before ChemotherapyEnzalutamide in Metastatic Prostate Cancer Before Chemotherapy
Enzalutamide in Metastatic Prostate Cancer Before ChemotherapyAvella Specialty Pharmacy
 
GnRH Agonists & Antagonists
GnRH Agonists & AntagonistsGnRH Agonists & Antagonists
GnRH Agonists & AntagonistsManas Nath
 

Destaque (20)

Flutamide
FlutamideFlutamide
Flutamide
 
Tb treatment
Tb treatmentTb treatment
Tb treatment
 
Drugs.com : Metformies
Drugs.com : MetformiesDrugs.com : Metformies
Drugs.com : Metformies
 
Ar v7
Ar v7Ar v7
Ar v7
 
Prescribing Information
Prescribing InformationPrescribing Information
Prescribing Information
 
Prostate Cancer: Keep Takling The Androgenic Nature
Prostate Cancer: Keep Takling The Androgenic NatureProstate Cancer: Keep Takling The Androgenic Nature
Prostate Cancer: Keep Takling The Androgenic Nature
 
Prostate cancer
Prostate cancer   Prostate cancer
Prostate cancer
 
Research2
Research2Research2
Research2
 
crpc
crpccrpc
crpc
 
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
 
World castration resistant prostate cancer therapeutics - market
World castration resistant prostate cancer therapeutics - market   World castration resistant prostate cancer therapeutics - market
World castration resistant prostate cancer therapeutics - market
 
Amiodarone
AmiodaroneAmiodarone
Amiodarone
 
ECCLU 2011 - K. Fizazi - Prostate cancer drug development
ECCLU 2011 - K. Fizazi - Prostate cancer drug developmentECCLU 2011 - K. Fizazi - Prostate cancer drug development
ECCLU 2011 - K. Fizazi - Prostate cancer drug development
 
ARV7 splice variant in CRPC
ARV7 splice variant in CRPCARV7 splice variant in CRPC
ARV7 splice variant in CRPC
 
Treatment of advanced metastatic prostate cancer
Treatment of advanced metastatic prostate cancerTreatment of advanced metastatic prostate cancer
Treatment of advanced metastatic prostate cancer
 
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
 
Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy
Enzalutamide in Metastatic Prostate Cancer Before ChemotherapyEnzalutamide in Metastatic Prostate Cancer Before Chemotherapy
Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy
 
Anti Cancer New Program
Anti Cancer New ProgramAnti Cancer New Program
Anti Cancer New Program
 
Clinical nutrition
Clinical nutritionClinical nutrition
Clinical nutrition
 
GnRH Agonists & Antagonists
GnRH Agonists & AntagonistsGnRH Agonists & Antagonists
GnRH Agonists & Antagonists
 

Semelhante a Sorafenib

chemo for study day finshed_.pptx
chemo for study day finshed_.pptxchemo for study day finshed_.pptx
chemo for study day finshed_.pptxadityasingla007
 
Haemostasis and thrombosis ppt
Haemostasis and thrombosis pptHaemostasis and thrombosis ppt
Haemostasis and thrombosis pptali7070
 
Drugs used in blood disorders by pharm bash
Drugs used in blood disorders by pharm bashDrugs used in blood disorders by pharm bash
Drugs used in blood disorders by pharm bashgybash
 
Coagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptxCoagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptxKarthiga M
 
anticoagulants acs (2) (1).pptx
anticoagulants acs (2) (1).pptxanticoagulants acs (2) (1).pptx
anticoagulants acs (2) (1).pptxsumiaru
 
Chapter 27 chemotherapy side effects dr lms
Chapter 27 chemotherapy side effects  dr lmsChapter 27 chemotherapy side effects  dr lms
Chapter 27 chemotherapy side effects dr lmsNilesh Kucha
 
ANTICOAGULATION...... slide presentation
ANTICOAGULATION...... slide presentationANTICOAGULATION...... slide presentation
ANTICOAGULATION...... slide presentationToqeerHussain22
 
Drug acting on inflammatory bowel disease
Drug acting on inflammatory bowel diseaseDrug acting on inflammatory bowel disease
Drug acting on inflammatory bowel diseaseAlisha Talwar
 
34933_Drug-induced Liver Disease(DILD).ppt
34933_Drug-induced Liver Disease(DILD).ppt34933_Drug-induced Liver Disease(DILD).ppt
34933_Drug-induced Liver Disease(DILD).pptMounikaReddy490655
 
Drugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organsDrugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organsUrmila Aswar
 
anticoagulants_22.ppt
anticoagulants_22.pptanticoagulants_22.ppt
anticoagulants_22.pptHurshidaShia
 

Semelhante a Sorafenib (20)

chemo for study day finshed_.pptx
chemo for study day finshed_.pptxchemo for study day finshed_.pptx
chemo for study day finshed_.pptx
 
Anticoagulants 22
Anticoagulants 22Anticoagulants 22
Anticoagulants 22
 
Aniticoagulants
AniticoagulantsAniticoagulants
Aniticoagulants
 
Warfarin
WarfarinWarfarin
Warfarin
 
Haemostasis and thrombosis ppt
Haemostasis and thrombosis pptHaemostasis and thrombosis ppt
Haemostasis and thrombosis ppt
 
Noac mine [autosaved]
Noac mine [autosaved]Noac mine [autosaved]
Noac mine [autosaved]
 
Antiarrhythmic drug
Antiarrhythmic drugAntiarrhythmic drug
Antiarrhythmic drug
 
Canc2
Canc2Canc2
Canc2
 
BiTE Presentation
BiTE PresentationBiTE Presentation
BiTE Presentation
 
Drugs used in blood disorders by pharm bash
Drugs used in blood disorders by pharm bashDrugs used in blood disorders by pharm bash
Drugs used in blood disorders by pharm bash
 
Coagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptxCoagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptx
 
anticoagulants acs (2) (1).pptx
anticoagulants acs (2) (1).pptxanticoagulants acs (2) (1).pptx
anticoagulants acs (2) (1).pptx
 
Chapter 27 chemotherapy side effects dr lms
Chapter 27 chemotherapy side effects  dr lmsChapter 27 chemotherapy side effects  dr lms
Chapter 27 chemotherapy side effects dr lms
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
ANTICOAGULATION...... slide presentation
ANTICOAGULATION...... slide presentationANTICOAGULATION...... slide presentation
ANTICOAGULATION...... slide presentation
 
Drug acting on inflammatory bowel disease
Drug acting on inflammatory bowel diseaseDrug acting on inflammatory bowel disease
Drug acting on inflammatory bowel disease
 
Painkillers
PainkillersPainkillers
Painkillers
 
34933_Drug-induced Liver Disease(DILD).ppt
34933_Drug-induced Liver Disease(DILD).ppt34933_Drug-induced Liver Disease(DILD).ppt
34933_Drug-induced Liver Disease(DILD).ppt
 
Drugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organsDrugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organs
 
anticoagulants_22.ppt
anticoagulants_22.pptanticoagulants_22.ppt
anticoagulants_22.ppt
 

Mais de Duraid Khalid

Mais de Duraid Khalid (7)

Rifampicin
RifampicinRifampicin
Rifampicin
 
Drugs safety in pregnancy
Drugs safety in pregnancyDrugs safety in pregnancy
Drugs safety in pregnancy
 
Dapsone1
Dapsone1Dapsone1
Dapsone1
 
Bromocriptine
BromocriptineBromocriptine
Bromocriptine
 
Gabapentin and pregablin
Gabapentin and pregablinGabapentin and pregablin
Gabapentin and pregablin
 
Sorafenib
SorafenibSorafenib
Sorafenib
 
TB treatment
TB treatmentTB treatment
TB treatment
 

Sorafenib

  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Fecal ( 77% ) and renal (19%) Excretion 25-48hours Half life Hepatic oxidation and glucuronidation (CYP3A4 mediated) Metabolism 99,5% Protein binding 29-49% Bioavailability
  • 8.
  • 9.
  • 10.
  • 11.